10+ years of scientific studies including induced pluripotent stem (iPS) cells and cancer biology. Worked 3 years for the renown pharmaceutical company Sanofi and participated to the foundation of Sanofi's first Stem Cell unit. Anthony Flamier studied pharmacology and toxicology at the university of Connecticut in the lab of Dr Rasmussen, a stem cell expert. More specifically, he created 36 patient-specific iPS cell lines for familial hypercholesterolemia and developed a new method to detect potential compound teratogenicity. Now a PhD, he developed a new Alzheimer's disease model as well as a new method to derive human retinal sheets in vitro.  Anthony Flamier has experience in the differentiation of human pluripotent stem cells into cortical neurons, retinal cells, liver cells and embryoid bodies.

20+ years of research, Dr. Gilbert Bernier performed is graduated studies in Molecular Biology at Montreal University where he characterized the gene mutated in the mouse neurological disorder dystonia musculorum. In 1997, he moved to the Max‐Planck Institute of Biophysical Chemistry in Germany to study developmental biology of the retina. Since 2001, he is heading the laboratory of stem cell and developmental biology at Maisonneuve‐Rosemont Hospital to exploit the potential of human pluripotent stem cells for the study and treatment of neurodegenerative diseases. Dr Bernier has also contributed to the characterization of Polycomb group proteins function in brain cancer, DNA repair, and premature ageing. He is Associate Professor at the Neuroscience Department of Montreal University since 2012.




Dr. Caouette did his doctorate in medicine at the University of Montreal. He then did his residency in family medicine at the University of Sherbrooke, then in emergency medicine with the University of Laval. From 2000 to 2011 he worked as a clinical teaching professor in the emergency medicine department of the university hospital center of Sherbrooke. Since then he has been doing clinical work in private practice. For the past four years he has been involved in degenerative disease research programs.


Hugues Beauregard, MD FRCP(M) CSPQ (E)

Jean-François Bélanger, MD

GILbert bernier, pHd: CEO and co-founder